MajorVitamin K antagonist anticoagulants×Non-steroidal anti-inflammatory drugs (NSAIDs)
Updated · Methodology
Mechanism
The Spanish acenocoumarol SmPCs, both the originator and a generic, list non-steroidal anti-inflammatory drugs (NSAIDs) among drugs that potentiate the anticoagulant effect of acenocoumarol or impair haemostasis. These drugs raise the risk of bleeding, including gastrointestinal bleeding (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The diclofenac SmPC classes diclofenac as an NSAID. Diclofenac inhibits prostaglandin synthesis and can itself cause ulcers, perforations and bleeding in the stomach and bowel (diclofenac SmPC, AEMPS). Clinical studies do not appear to show that diclofenac changes the action of anticoagulants, but there are reports of a higher risk of bleeding when the two are taken together (diclofenac SmPC, AEMPS). According to the US label, diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The risk of serious bleeding is higher with the combination than with either drug alone (diclofenac prescribing information, US Food and Drug Administration, FDA).
Symptoms
The main risk is bleeding, above all from the stomach and bowel. With non-steroidal anti-inflammatory drugs, including diclofenac, gastrointestinal bleeding, ulcers and perforations can occur at any time during treatment, sometimes fatally, with or without warning symptoms. The risk is higher in older people and rises with the dose (diclofenac summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older, with a history of gastrointestinal bleeding and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds and bleeding gums (acenocoumarol SmPC, AEMPS).
Management
The Spanish acenocoumarol SmPCs, both the originator and a generic, generally do not recommend combining acenocoumarol with non-steroidal anti-inflammatory drugs (NSAIDs) unless the combination is strictly indicated (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The diclofenac SmPC classes diclofenac as an NSAID (diclofenac SmPC, AEMPS). If the combination cannot be avoided, use close and frequent coagulation checks, for example twice a week, both after diclofenac is started and after it is stopped. While the two drugs are taken together, test the international normalised ratio (INR) more often than usual (acenocoumarol SmPCs, AEMPS). Use diclofenac with special caution and careful monitoring with coumarin-type oral anticoagulants (diclofenac SmPC, AEMPS), and watch for signs of bleeding (diclofenac prescribing information, US Food and Drug Administration, FDA). Use the lowest effective dose of diclofenac for the shortest possible time, and start older people on the lowest effective dose (diclofenac SmPC, AEMPS). With other drugs that raise gastrointestinal risk, consider a protective agent such as misoprostol or a proton pump inhibitor (diclofenac SmPC, AEMPS). Proton pump inhibitors such as omeprazole, however, may themselves potentiate acenocoumarol (acenocoumarol SmPCs, AEMPS). Stop diclofenac at once if gastrointestinal bleeding or an ulcer occurs (diclofenac SmPC, AEMPS). Peptic ulcer and gastrointestinal bleeding are contraindications to acenocoumarol, and active gastrointestinal ulcer, bleeding or perforation are contraindications to diclofenac (acenocoumarol and diclofenac SmPCs, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Diclofenac sodium delayed-release tablets prescribing information (2021)– FDA, DailyMed setid a57b897e-0cbe-4ac3-969f-b00357a0cfa8 (Actavis Pharma), versión 26, texto 08/2021, Warnings (Gastrointestinal Bleeding, Ulceration, and Perforation; Hematologic Toxicity), Precautions (Drug Interactions; Information for Patients)
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.4 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.4 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.3 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.3 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.3
- AEMPS: Ficha técnica: Diclofenaco, Voltarén Retard 100 mg (nº registro 56562), secciones 4.3, 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 56562 (Voltarén Retard 75 mg y 100 mg comprimidos de liberación modificada, Novartis Farmacéutica), revisión 08/2025, secciones 4.2, 4.3, 4.4, 4.5 y 5.1